Cross-sectional case-control studies (Blue)
In this study, the authors aimed to determine the rates of cerebral venous sinus thrombosis (CVT) and its impact on outcomes in patients with COVID-19. De-identified patient information was extracted on March 1st, 2021 using the TriNetX COVID-19 Research Network platform. From this dataset, the authors identified 667,551 COVID-19 patients of which 42 had CVT, and 65,796,480 non COVID-19 patients of which 1022 had CVT (0.0001 vs 0.000002, OR = 40.99 [95% CI = 30.11 – 55.81], p < 0.00001). Among the 42 COVID-19 patients with CVT, 24 (57.1%) were females and 28 (66.6%) were Caucasians. A significantly higher prevalence of hypertension (p = 0.0278) and diabetes mellitus (p = 0.0107) was observed in patients suffering from CVT with COVID-19 compared to the non COVID-19 cohort. Moreover, a significantly higher mortality rate was observed in patients suffering from CVT with COVID-19 compared to the non COVID-19 cohort (11.9% vs 2.8%, OR = 4.627 [95% CI = 1.320–13.032], p = 0.0011) suggesting that CVT associated with COVID-19 infection has higher mortality rate.
Archana Hinduja, Krishna Nalleballe, Sanjeeva Onteddu, Sukanthi Kovvuru, Omar Hussein, Impact of cerebral venous sinus thrombosis associated with COVID-19, Journal of the Neurological Sciences, Volume 425, 2021, 117448, ISSN 0022-510X, https://doi.org/10.1016/j.jns.2021.117448